Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference

Rhea-AI Summary

Imago BioSciences, a clinical-stage biopharmaceutical firm, announced that CEO Hugh Y. Rienhoff, Jr., M.D. will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 10:40 a.m. ET. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for 90 days afterward.

The company focuses on developing treatments for myeloproliferative neoplasms (MPNs), with Bomedemstat as its lead candidate, targeting lysine-specific demethylase 1 (LSD1). Bomedemstat has received several designations from the FDA and EMA.

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021, at 10:40 a.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.imagobio.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California.

Contacts

INVESTORS
Laurence Watts
Gilmartin Group, LLC.
laurence@gilmartinir.com

MEDIA
Will Zasadny
Canale Communications
will.zasadny@canalecomm.com

Source: Imago BioSciences, Inc.

FAQ

What is the date and time of Imago's presentation at the Stifel 2021 Virtual Healthcare Conference?

Imago's presentation is scheduled for November 16, 2021, at 10:40 a.m. ET.

How can I access Imago's presentation at the Stifel conference?

The presentation can be accessed via a live audio webcast on Imago's Investor Relations section of their website.

What is Bomedemstat and its significance for Imago?

Bomedemstat is Imago's lead product candidate targeting LSD1, designed for treating myeloproliferative neoplasms, and has received Orphan Drug and Fast Track designations.

What designations has Bomedemstat received from regulatory agencies?

Bomedemstat has received U.S. FDA Orphan Drug and Fast Track Designations, EMA Orphan Designation, and PRIME designation for the treatment of myelofibrosis.

What types of diseases is Imago focused on treating?

Imago focuses on developing treatments for myeloproliferative neoplasms, which are chronic bone marrow cancers.